Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is BVF Inc. IL's 7th Largest Position

BVF Inc. IL grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 2.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,900,015 shares of the company's stock after purchasing an additional 49,848 shares during the period. Protagonist Therapeutics makes up about 2.5% of BVF Inc. IL's holdings, making the stock its 7th largest position. BVF Inc. IL owned about 3.19% of Protagonist Therapeutics worth $73,341,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Bellevue Group AG raised its holdings in Protagonist Therapeutics by 92.1% during the fourth quarter. Bellevue Group AG now owns 23,718 shares of the company's stock worth $916,000 after purchasing an additional 11,372 shares during the last quarter. Bank of America Corp DE increased its position in shares of Protagonist Therapeutics by 13.4% in the fourth quarter. Bank of America Corp DE now owns 134,872 shares of the company's stock valued at $5,206,000 after buying an additional 15,970 shares in the last quarter. Freestone Grove Partners LP acquired a new position in shares of Protagonist Therapeutics during the 4th quarter worth $256,000. AQR Capital Management LLC boosted its position in shares of Protagonist Therapeutics by 9.4% in the 4th quarter. AQR Capital Management LLC now owns 150,097 shares of the company's stock worth $5,794,000 after buying an additional 12,926 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Protagonist Therapeutics by 8.4% in the 4th quarter. Northern Trust Corp now owns 628,580 shares of the company's stock valued at $24,263,000 after acquiring an additional 48,491 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company's stock.

Insider Buying and Selling at Protagonist Therapeutics

In related news, CFO Asif Ali sold 1,756 shares of the firm's stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total value of $80,776.00. Following the transaction, the chief financial officer now owns 61,065 shares in the company, valued at approximately $2,808,990. This trade represents a 2.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $54.25, for a total transaction of $217,000.00. Following the transaction, the director now directly owns 13,130 shares in the company, valued at approximately $712,302.50. This trade represents a 23.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,532 shares of company stock valued at $3,665,786. Company insiders own 5.40% of the company's stock.

Protagonist Therapeutics Stock Performance

NASDAQ PTGX traded up $1.08 during trading hours on Wednesday, hitting $43.09. 1,360,357 shares of the company's stock were exchanged, compared to its average volume of 868,864. The firm has a market capitalization of $2.67 billion, a P/E ratio of 16.20 and a beta of 2.65. The business's 50 day moving average is $46.65 and its 200-day moving average is $42.76. Protagonist Therapeutics, Inc. has a 12-month low of $25.75 and a 12-month high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.31. The company had revenue of $28.32 million for the quarter, compared to analyst estimates of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. As a group, equities research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on PTGX shares. BTIG Research set a $73.00 target price on shares of Protagonist Therapeutics in a research report on Monday, March 3rd. JPMorgan Chase & Co. upped their target price on Protagonist Therapeutics from $53.00 to $57.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Wedbush reissued an "outperform" rating and set a $70.00 price target on shares of Protagonist Therapeutics in a research report on Friday, March 28th. The Goldman Sachs Group cut their price target on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, February 24th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $65.44.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.